Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2019
Price : $35 *
At a glance
- Drugs Interferon alpha-2b (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 01 Apr 2018 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.